ARID1A is an inclusion eligibility criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for synovial sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and synovial sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for synovial sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and synovial sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SMARCA2 is an inclusion eligibility criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCA4 is an inclusion eligibility criterion in 2 clinical trials for synovial sarcoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCA4 status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 3 clinical trials for synovial sarcoma, of which 2 are open and 1 is closed. Of the trials that contain SMARCB1 status and synovial sarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

SS18 is an inclusion eligibility criterion in 4 clinical trials for synovial sarcoma, of which 3 are open and 1 is closed. Of the trials that contain SS18 status and synovial sarcoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

SSX1 is an inclusion eligibility criterion in 4 clinical trials for synovial sarcoma, of which 3 are open and 1 is closed. Of the trials that contain SSX1 status and synovial sarcoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

SSX2 is an inclusion eligibility criterion in 3 clinical trials for synovial sarcoma, of which 2 are open and 1 is closed. Of the trials that contain SSX2 status and synovial sarcoma as inclusion criteria, 3 are phase 1 (2 open) [3].

SSX2B is an inclusion eligibility criterion in 2 clinical trials for synovial sarcoma, of which 1 is open and 1 is closed. Of the trials that contain SSX2B status and synovial sarcoma as inclusion criteria, 2 are phase 1 (1 open) [3].

SSX4 is an inclusion eligibility criterion in 3 clinical trials for synovial sarcoma, of which 2 are open and 1 is closed. Of the trials that contain SSX4 status and synovial sarcoma as inclusion criteria, 3 are phase 1 (2 open) [3].